Medical Patent Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Liver Cancer
Can-Fite Receives FDA Approval to Conduct Phase I Study With CF102
January 25th, 2008
Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, is making progress with CF102, the drug it develops for the treatment of liver cancer. Can-Fite reported that an approval was granted by the Food and Drug Administration (FDA) to conduct a phase I study with its second pipeline drug, CF102. CF102, which was developed based on Can-Fite's platform technology, is a targeted drug that binds with high affinity to the A3 adenosine receptor. This receptor is highly expressed on the surface of cancer cells but not on normal cells. CF102 binds to its target on cancer cells and triggers programmed cell death (apoptosis). ...
Source: Medical Patent Business Week (2008-01-25)
|
